Profile data is unavailable for this security.
About the company
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).
- Revenue in USD (TTM)2.15bn
- Net income in USD-811.94m
- Incorporated1998
- Employees7.37k
- LocationEnovis Corp2711 CENTERVILLE ROAD, SUITE 400WILMINGTON 19808United StatesUSA
- Phone+1 (302) 252-9160
- Fax+1 (301) 323-9001
- Websitehttps://www.enovis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Establishment Labs Holdings Inc | 170.24m | -89.10m | 1.26bn | 1.03k | -- | 32.65 | -- | 7.40 | -3.10 | -3.10 | 5.94 | 1.33 | 0.536 | 0.7032 | 2.98 | 167,225.00 | -28.06 | -31.53 | -34.39 | -39.32 | 66.35 | 65.46 | -52.34 | -45.09 | 2.05 | -2.41 | 0.8511 | -- | 0.5292 | 13.14 | -7.76 | -- | 17.33 | -- |
| Artivion Inc | 390.08m | -21.36m | 1.31bn | 1.60k | -- | 4.46 | 559.42 | 3.36 | -0.5102 | -0.5102 | 9.31 | 6.89 | 0.4953 | 1.72 | 4.81 | 243,802.50 | -2.72 | -2.47 | -2.90 | -2.66 | 63.94 | 65.02 | -5.49 | -5.89 | 3.95 | 0.8589 | 0.5197 | -- | 9.75 | 7.06 | 56.37 | -- | 6.75 | -- |
| Evolent Health Inc | 2.40bn | -140.48m | 1.38bn | 4.50k | -- | 1.46 | -- | 0.577 | -1.22 | -1.22 | 20.86 | 9.74 | 0.9057 | -- | 5.59 | 533,052.70 | -4.11 | -5.93 | -5.59 | -8.00 | 15.25 | 21.07 | -4.54 | -7.16 | -- | 0.276 | 0.4206 | -- | 30.09 | 30.04 | 34.31 | -- | -6.87 | -- |
| Omnicell Inc | 1.14bn | 21.18m | 1.40bn | 3.62k | 66.01 | 1.11 | 12.75 | 1.23 | 0.4521 | 0.4521 | 24.39 | 26.84 | 0.5122 | 6.62 | 4.54 | 309,470.00 | 0.9553 | 1.07 | 1.24 | 1.40 | 43.24 | 45.58 | 1.87 | 1.93 | 1.23 | -- | 0.2135 | 0.00 | -3.04 | 4.39 | 161.51 | -27.21 | -3.06 | -- |
| BioSig Technologies Inc | 26.00k | -9.79m | 1.42bn | 5.00 | -- | 96.90 | -- | 54,598.31 | -0.6236 | -0.6236 | 0.0016 | 0.1118 | 0.0087 | -- | 0.4228 | 5,200.00 | -323.76 | -266.73 | -- | -392.02 | 50.00 | -- | -37,400.00 | -20,163.95 | -- | -1,551.13 | 0.00 | -- | 122.22 | -- | 63.81 | -- | -- | -- |
| AtriCure Inc | 480.08m | -38.18m | 1.57bn | 1.30k | -- | 3.46 | -- | 3.28 | -0.8101 | -0.8101 | 10.19 | 9.19 | 0.8115 | 1.65 | 8.09 | 369,289.20 | -6.45 | -3.84 | -7.20 | -4.25 | 74.76 | 74.53 | -7.95 | -7.13 | 2.88 | -21.61 | 0.1335 | -- | 16.55 | 15.05 | -46.85 | -- | 14.00 | -- |
| 10X Genomics Inc | 624.66m | -157.04m | 1.60bn | 1.31k | -- | 2.27 | -- | 2.56 | -1.30 | -1.30 | 5.15 | 5.74 | 0.6841 | 2.50 | 8.68 | 478,301.70 | -17.20 | -25.61 | -19.51 | -29.19 | 68.36 | 74.03 | -25.14 | -47.52 | 4.68 | -- | 0.00 | -- | -1.28 | 19.96 | 28.41 | -- | -20.72 | -- |
| Alphatec Holdings Inc | 642.27m | -165.54m | 1.61bn | 867.00 | -- | -- | -- | 2.50 | -1.15 | -1.15 | 4.45 | -0.4243 | 0.8234 | 1.23 | 7.01 | 740,790.10 | -21.22 | -27.43 | -26.85 | -34.69 | 68.96 | 66.99 | -25.77 | -39.40 | 1.67 | -11.66 | 1.13 | -- | 26.81 | 40.07 | 13.14 | -- | 48.19 | -- |
| Conmed Corp | 1.32bn | 118.75m | 1.68bn | 3.90k | 14.24 | 1.72 | 8.81 | 1.28 | 3.82 | 3.82 | 42.27 | 31.61 | 0.5713 | 1.71 | 5.69 | 337,435.40 | 5.16 | 1.85 | 5.89 | 2.11 | 56.14 | 55.15 | 9.02 | 3.44 | 1.00 | 5.04 | 0.4771 | 63.56 | 5.00 | 6.47 | 105.44 | 35.85 | -8.20 | 0.00 |
| Premier Inc | 1.10bn | 104.27m | 1.81bn | 2.90k | 21.77 | 1.19 | 7.75 | 1.65 | 1.01 | 0.5705 | 11.31 | 18.50 | 0.3419 | -- | 2.51 | 379,330.30 | 3.58 | 7.08 | 4.78 | 8.95 | 70.96 | 61.29 | 10.48 | 16.05 | -- | -- | 0.38 | 27.32 | 0.7684 | 2.03 | -31.70 | -11.93 | -2.76 | -- |
| LeMaitre Vascular Inc | 226.26m | 45.16m | 1.91bn | 651.00 | 42.70 | 5.49 | 34.67 | 8.43 | 1.98 | 1.98 | 9.90 | 15.38 | 0.4973 | 1.12 | 6.92 | 347,551.50 | 9.93 | 9.09 | 10.52 | 9.89 | 68.80 | 66.24 | 19.96 | 16.64 | 13.83 | -- | 0.3258 | 38.38 | 13.63 | 13.40 | 46.28 | 19.68 | 13.11 | 13.79 |
| Enovis Corp | 2.15bn | -811.94m | 1.92bn | 7.37k | -- | 0.7342 | -- | 0.894 | -14.52 | -14.47 | 38.53 | 45.83 | 0.4154 | 1.63 | 5.27 | 291,867.90 | -15.67 | -3.14 | -17.40 | -3.56 | 55.68 | 52.01 | -37.72 | -9.77 | 1.32 | 0.9747 | 0.3462 | -- | 23.46 | -8.73 | -1,423.10 | -- | 7.58 | -- |
| UFP Technologies Inc | 547.56m | 63.47m | 1.92bn | 4.15k | 30.63 | 5.33 | 24.12 | 3.51 | 8.15 | 8.15 | 70.31 | 46.80 | 1.04 | 4.75 | 7.06 | 132,069.50 | 12.09 | 10.12 | 13.83 | 11.53 | 28.99 | 27.07 | 11.59 | 10.64 | 1.45 | 8.86 | 0.3364 | 0.00 | 26.08 | 20.52 | 31.29 | 24.46 | 10.82 | -- |
| Novocure Ltd | 621.71m | -164.19m | 1.97bn | 1.49k | -- | 5.45 | -- | 3.18 | -1.51 | -1.51 | 5.72 | 3.25 | 0.5246 | 3.47 | 8.31 | 417,816.50 | -13.85 | -9.61 | -22.39 | -11.84 | 77.16 | 77.57 | -26.41 | -19.32 | 1.41 | -- | 0.6446 | -- | 18.82 | 11.49 | 18.55 | -- | 32.52 | -- |
| Quidelortho Corp | 2.76bn | -358.70m | 2.04bn | 6.60k | -- | 0.6799 | 23.49 | 0.7385 | -5.33 | -5.33 | 41.05 | 44.40 | 0.42 | 2.56 | 8.74 | 418,893.90 | -5.45 | 0.0044 | -6.33 | 0.005 | 46.94 | 59.13 | -12.97 | 0.009 | 0.6637 | 0.535 | 0.4548 | 0.00 | -7.17 | 39.07 | -20,216.83 | -- | 48.27 | -- |
| LivaNova PLC | 1.28bn | -222.15m | 2.52bn | 2.90k | -- | 2.43 | -- | 1.97 | -4.09 | -4.09 | 23.37 | 18.97 | 0.5083 | 2.55 | 6.20 | 439,786.20 | -8.85 | -4.14 | -11.25 | -5.03 | 69.33 | 67.61 | -17.42 | -9.04 | 1.37 | -- | 0.3781 | -- | 8.66 | 2.94 | 260.39 | -- | 10.98 | -- |
Data as of Jul 03 2025. Currency figures normalised to Enovis Corp's reporting currency: US Dollar USD
62.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2025 | 6.52m | 11.45% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2025 | 6.21m | 10.90% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 6.01m | 10.55% |
| American Century Investment Management, Inc.as of 31 Mar 2025 | 3.52m | 6.19% |
| Davenport & Co. LLCas of 31 Mar 2025 | 3.07m | 5.39% |
| Dimensional Fund Advisors LPas of 31 Mar 2025 | 2.82m | 4.94% |
| Royce & Associates LPas of 31 Mar 2025 | 2.49m | 4.37% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 1.89m | 3.33% |
| Diamond Hill Capital Management, Inc.as of 31 Mar 2025 | 1.87m | 3.29% |
| Hood River Capital Management LLCas of 31 Mar 2025 | 1.44m | 2.53% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
